Abstract Polymorphisms in ApoE are highly correlated with the progression of neurodegenerative disease, in particular Alzheimer's disease. Little is known, however, about the role of ApoE or cholesterol metabolism on brain neurochemistry in general. To better understand the role of lipoprotein and cholesterol metabolism in the brain, we profiled 6 and 12-week old Apoe KO and Ldlr KO mouse models via unbiased metabolomics to determine which metabolites were affected at an early age to identify those that may play a role in triggering pathology later in life. Steady-state metabolomics revealed only subtle differences among Apoe KO, Ldlr KO and WT mouse brains. Ldlr KO mice exhibited alterations in metabolites involved in neurotransmitter, amino acid and cholesterol metabolism. In contrast, Apoe KO mice only showed subtle changes in amino acid and neurotransmitter metabolism. These subtle changes in a broad range of metabolites indicate that ApoE and Ldl-R alone may not play a significant role in these mouse models at an early age, but instead require the cumulative effect from different pathways that lead to dysfunction at a much later stage of life.
Background
The balance and maintenance of lipids within the nervous system is critical for neural development, cognition and disease progression. There is clear evidence for important interactions between diet, neurometabolism and human disease, but the mechanisms that link diet to neurological function and pathology remain poorly understood. In fact, the intracellular and intercellular metabolic pathways that regulate central carbon flux in the brain remain poorly defined (Wegener 1983 ).
Alzheimer's disease (AD) is a progressive neurodegenerative disease that has been strongly associated with metabolic alterations (Canevari and Clark 2007; Fryer et al. 2005) and is characterized by the deposition of amyloid plaques in the brain that are formed from fibrillary Aβ peptides (Canevari and Clark 2007) . Several studies have demonstrated an association between lipid metabolism in the central nervous system (CNS) and AD (Cheng et al. 2010 (Cheng et al. , 2013 Han 2004; Han et al. 2002 Han et al. , 2011 Burgess et al. 2006) . The mammalian brain is rich in lipids, and mutations in lipid metabolizing enzymes are known to cause debilitating neurological diseases. Cholesterol homeostasis in the brain is regulated largely by de novo synthesis in glia along with the synthesis of apolipoprotein-E (ApoE) (Russell et al. 2009 ). Numerous studies have demonstrated that the elevation of cholesterol in serum is associated with increased Aβ production and increased risk of AD (Canevari and Clark 2007; Kaliyamurthi et al. 2012) . Furthermore, several genes involved in cholesterol metabolism have been identified that show changes in sporadic AD patients, indicating that cholesterol metabolism may play a significant role in the pathogenesis of late-onset AD (Wisniewski et al. 2013 ).
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Many studies have focused on the role of ApoE in the CNS following the discovery that the Apoε4 allele in humans significantly increases the risk of developing AD later in life. ApoE is linked to late-onset AD because it can potentially act as an Aβ chaperone and influence Aβ metabolism in the CNS (Canevari and Clark 2007; Fryer et al. 2005; Hartmann et al. 2007 ). ApoE, a 34 kDa secreted glycoprotein, is involved in the uptake and degradation of lipoproteins via receptor-mediated endocytosis (Rebeck et al. 2006) and is expressed in the liver and the brain (Han 2004; Orth and Bellosta 2012) . In the CNS, ApoE is thought to transport lipoproteins and maintain lipid homeostasis in the developing nervous system (Han 2004; Orth and Bellosta 2012; Fan et al. 2001; Mulder et al. 2004; Puglielli et al. 2003; Wahrle et al. 2004 ). The Ldl-R is a cell surface receptor that assists in the endocytosis of the ApoE-cholesterol complex into cells (Canevari and Clark 2007; Fryer et al. 2005; Orth and Bellosta 2012; Spencer and Verma 2007) , and mutations in Ldl-R result in severe familial hypercholesterolemia. Previous studies have demonstrated that a lack of Ldl-R induced an increase in Aβ aggregation and deposition, indicating that Ldl-R plays a crucial role in Aβ regulation in the brain (Fryer et al. 2005) .
Although a great number of studies have tried to elucidate the role of ApoE and Ldl-R in the development of AD, the molecular mechanisms by which ApoE and Ldl-R are involved remain elusive. Here we used an unbiased metabolomic approach to broadly determine the consequence of ApoE and Ldl-R deletion to gain insight into the biochemical and physiological-metabolic roles of ApoE and Ldl-R within the central nervous system. Both Apoe and Ldlr KO mouse models result in systemic hypercholesterolemia. Utilizing young mice at several time points, a small number of changes in multiple metabolites were seen from different pathways in Apoe and Ldlr KO brains. These consistent metabolic alterations may provide insight into the molecular mechanisms by which ApoE and Ldl-R contribute to the progression of AD over the course of aging.
Methods

Animals and metabolites
Apoe KO, Ldlr KO and WT mice were purchased from Jackson Laboratory and maintained on a standard lab chow (Harlan 2018) . At 6 and 12 weeks of age, serum, brain and liver were collected and rapidly frozen in liquid nitrogen. Total cholesterol (Wako) from serum was measured colorimetrically. Metabolomic analysis was performed as previously described (Eckel-Mahan et al. 2012; Ellis et al. 2013; Lee and Wolfgang 2012) . All procedures were performed in accordance with the NIH's Guide for the Care and Use of Laboratory Animals and under the approval of the Johns Hopkins School of Medicine Animal Care and Use Committee.
Western blot analysis
Liver and brain were homogenized in Media I (10 mM Tris, 1 mM EDTA, 0.25 M sucrose) with protease inhibitors (Complete Mini, Roche). All samples were spun down at 10, 000 rpm for 20 min, and supernatant was collected and assayed by the Pierce BCA Protein Assay Kit (Thermo Scientific) to determine the concentration of protein. A total of 30 μg of protein for liver and 50 μg of protein for brain was subjected to SDS-PAGE and transferred to a nitrocellulose (Protran BA 83, Whatman) or a polyvinylidene difluoride (PVDF) membrane blocked with 5 % milk-TBST (Tris-buffer saline with Tween 20). The blots were probed with the following primary antibodies (1:1000 to 1:2000): Ldl-R (R&D Systems), ApoE (Santa Cruz), ACC (Cell signaling), ACOT7 (Ellis et al. 2013) , and Cpt1c (Wolfgang et al. 2006; Reamy and Wolfgang 2011) using the appropriate secondary antibodies conjugated to horseradish peroxidase (HRP). Fasn (BD Biosciences) and Hsc70 (Santa Cruz) used the Cy3 (Life Technologies) fluorescent secondary antibody.
Statistical analysis
Metabolomic analyses utilized two-way ANOVA to identify biochemicals exhibiting significant interactions and main effects for experimental parameters of genotype and time. The remaining data performed pair-wise comparisons between Apoe KO or Ldlr KO to WT using Welch's two-sample t-tests. P-values below the significance level of 0.05 were interpreted to have enough evidence to conclude that the data had a statistically different mean (i.e. statistically significant).
Results
Apoe and Ldlr KO mice
To understand the endogenous function of ApoE and Ldl-R, we performed metabolomic studies on brains of Apoe KO, Ldlr KO and WT control mice at 6 and 12 weeks of age. We chose mice at an early age to better understand proximal neurometabolic changes that could later correlate with neuropathology before too many confounding secondary changes occurred. Apoe KO mice and Ldlr KO mice demonstrated a loss of ApoE and Ldl-R protein in the liver respectively (Fig. 1a) . It has been previously shown that Ldlr KO mice exhibit increased extracellular levels of ApoE in the brain (Fryer et al. 2005) . Consistent with this finding, we saw increased levels of ApoE in both the liver (Fig. 1a ) and brain (data not shown) in Ldlr KO mice. Previous studies have shown that Apoe and Ldlr KO mouse models show hypercholesterolemia, since they are not capable of catabolizing cholesterol-rich lipoproteins. Both Apoe KO and Ldlr KO mice showed increased levels of total cholesterol in the serum as early as 6 weeks of age compared to WT littermates (Fig. 1b) . A large number of studies have shown that Apoe KO mice are hyperlipidemic since ApoE plays a central role in lipoprotein metabolism (Pendse et al. 2009 ). These data show that even at an early age, Apoe KO and Ldlr KO mice exhibit metabolic dysfunction.
Additionally, we probed via western blot canonical pathways contributing to de novo fatty acid biosynthesis that are often changed and are seen as energy sensing pathways. We did not observe changes in the levels of acetyl-CoA carboxylase (ACC) or fatty acid synthase (Fasn) in young Apoe KO o r L d l r K O m o u s e b r a i n s ( F i g . 2 a ) . C a r n i t i n e palmitoyltransferase 1c (Cpt1c) and acyl-CoA thioesterase 7 (Acot7), which are involved in neuron-specific fatty acid metabolic pathways, were not changed in young Apoe KO or Ldlr KO mouse brains (Fig. 2b) . These data show that the major fatty acid handling pathways are largely unaffected at the protein level in young Apoe KO or Ldlr KO mouse brains.
Loss of Ldlr and Apoe have moderate effects on cholesterol homeostasis
To understand the most proximal effects of Apoe and Ldlr on brain neurochemistry, we assayed the steady-state metabolic alterations in young WT, Apoe KO and Ldlr KO mouse brains at 6 and 12 weeks of age. Surprisingly, we did not find large changes in cholesterol or cholesterol metabolites in Apoe KO or Ldlr KO mouse brains (Fig. 3a) . In fact, some of the key biosynthetic intermediates were suppressed in 6-week old Apoe KO brains and resolved by 12 weeks (Fig. 3a) . The brain is rich in polyunsaturated fatty acids (PUFAs), particularly arachidonic acid (AA) (20:4n-6) and docosahexaenoic acid (DHA) (22:6n-3). Within the brain, these PUFAs regulate membrane fluidity, neuronal survival and signal transduction. Deficits and altered metabolism of AA and DHA fatty acids are associated with impaired neurodevelopment and several neurological disorders (Hartmann et al. 2007; Alakbarzade et al. 2015; Guemez-Gamboa et al. 2015; Hogyes et al. 2003) . Several studies have demonstrated that depletions in these essential PUFAs contribute to the pathogenesis of AD (Hartmann et al. 2007; Soderberg et al. 1991; Tully et al. 2003) . We were able to identify that ω3 derivatives eicosapentaenoate (EPA; 20:5n3), docosapentaenoate (n3 DPA; 22:5n3), AA and DHA were increased in Ldlr KO 12-week brains relative to 6-week brains. However, the Ldlr KO and Apoe KO mouse brains did not show any significant changes in these metabolites that were genotype specific (Fig. 3b) . These results indicate a strong homeostatic mechanism to maintain brain lipids even under strong genetic perturbations.
Loss of Ldlr and Apoe exhibits subtle changes in neurotransmitter metabolism
Excitatory neurotransmission via glutamate is tightly regulated via glutamate-glutamine cycling. We observed an increase in glutamine and N-acetyl glutamine levels, metabolites Fig. 2 Fatty acid metabolic pathways are not affected in young Apoe and Ldlr KO mice. a Western blot analysis of proteins involved in de novo fatty acid biosynthesis on control, Ldlr and Apoe KO mouse brains at 12 weeks of age. b Western blot analysis of Cpt1c and Acot7 from brains of control, Ldlr and Apoe KO mice at 12 weeks of age. All blots used Hsc70 for loading control Fig. 1 Characterization of control, Apoe KO and Ldlr KO mice. a ApoE and Ldl-R protein from homogenized livers of control, Ldlr and Apoe KO mice at 6 and 12 weeks of age were analyzed by western blot using antiApoE and anti-LdlR antibody. Hsc70 was used for loading control. b Cholesterol levels in serum of control, Ldlr and Apoe KO mice at 6 and 12 weeks of age (n = 6). Data are expressed as mean ± SEM. **p < 0.001. Open bars represent control, grey bars represent loss of Ldl-R and black bars represent loss of ApoE derived from glutamate, in Apoe KO mice at 6 weeks and Ldlr KO at 12 weeks, indicating a possible yet subtle perturbation in the glutamate-glutamine cycle (Fig. 4) . These data show a relatively normal excitatory neurotransmitter metabolism.
Histamine is a neurotransmitter that is generally involved in regulatory mechanisms in the brain. Previous studies demonstrated that a decrease in brain histamine contributes to cognitive decline in AD directly or through the cholinergic system (Panula et al. 1998) . 1-methylimidazoleacetate is a breakdown product of histamine and we observed increased 1-methylimidazoleacetate levels in brain samples of both Ldlr KO and Apoe KO mice at 6 and 12 weeks relative to control mice, indicating altered histamine metabolism (Fig. 5a) . Carnosine, anserine and ergothioneine are also products Fig. 3 Loss of ApoE or Ldl-R does not perturb the homeostatic mechanisms that maintain brain lipids. a Biochemicals involved in the cholesterol pathway from control, Ldlr KO and Apoe KO brains of mice at 6 and 12 weeks of age were compared through metabolomic analysis. b Biochemicals from 6-to 12-week old control, Ldlr KO and Apoe KO mouse brains involved in the eicosanoid pathway. Letters and lines indicate differences (p < 0.05) between control and Ldlr KO or control and Apoe KO mice (n = 6/group) derived from histidine (Fig. 5b) . There was an overall increase in these metabolites in both KO models at 12 weeks of age (Fig. 5a ). These data suggest subtle changes in histadine metabolism in the brains of Ldlr KO and Apoe KO mice.
Loss of Ldlr and Apoe exhibits altered lysine metabolism
Metabolomic studies in humans between normal and AD patients have shown that there are significant alterations in lysine metabolism (Trushina et al. 2013 ). 2-aminoadipate and glutaroyl carnitine are catabolites along the lysine metabolic pathway. In Ldlr KO and Apoe KO mouse models, we observed that 2-aminoadipate and glutaroyl carnitine were significantly reduced in both Ldlr and Apoe KO mice at 6 and 12 weeks relative to wild type controls (Fig. 6 ). These were some of the most significantly altered metabolites in the Ldlr KO and Apoe KO brain metabolome. Pipecolate and lysine were not altered at either age in either genotype (Fig. 6) . Additionally, 2-aminobutyrate was significantly increased in 12-week old Ldlr KO and Apoe KO mouse brains and 3-dehydrocarnitine was significantly increased in 6 and 12-week old Ldlr KO and Apoe KO mouse brains (Fig. 6) . These data indicate altered brain bioenergetics and possible altered energy homeostatic mechanisms. Fig. 4 Apoe KO and Ldlr KO mice do not exhibit alterations in excitatory neurotransmission via glutamate-glutamine cycling. Subtle changes in biochemicals glutamine and N-acetylglutamate were observed through metabolomic analysis in brains of 6 and 12-week old mouse brains of control, Ldlr KO and Apoe KO mice. Letters and lines indicate differences (p < 0.05) between control and Ldlr KO or control and Apoe KO mice (n = 6/group)
Discussion
The absence of Ldl-R or ApoE disrupts cholesterol and lipid homeostasis. A decrease in cholesterol levels in neurons affects Aβ levels in the brain (Kaether and Haass 2004) , and it has been shown that hypercholesterolemia potentiates tauhyperphosphorylation and Aβ production in the brain (Orth and Bellosta 2012) . There was a significant increase in plasma total cholesterol levels in both the Ldlr and Apoe KO animals compared to their WT littermates even at early time points. The Ldl-R is one of the main receptors that interacts with the lipoprotein complex to internalize and degrade these molecules in target cells. In this context, the absence of Ldl-R could cause a blockage of lipoprotein uptake, increasing plasma cholesterol levels. ApoB and ApoE are the two main apolipoproteins that globally regulate cholesterol and lipid homeostasis, ApoE being one of the primary apolipoproteins in the brain that transfers cholesterol between the cells of the brain (Russell et al. 2009 ). Therefore, the absence of ApoE could severely impede cholesterol uptake, causing an increase in plasma cholesterol levels.
In the brain, cholesterol and cholesterol metabolites were decreased in Apoe KO and Ldlr KO mice, especially at 12 weeks of age. Cholesterol is tightly regulated in the brain by the blood brain barrier, which does not allow lipoprotein cholesterol uptake from serum, and is mostly derived by de novo synthesis (Orth and Bellosta 2012, 40) . Depletion of cholesterol leads to synaptic and dendritic spine degeneration, failed neurotransmission and decreased synaptic plasticity (Russell et al. 2009; Koudinov and Koudinova 2005) . Our metabolomic data show that in both KO mouse models, there is a decreasing trend with age in cholesterol and cholesterol precursor levels. In particular, the level of cholesterol and desmosterol were lower than WT levels. In humans and rodents with AD, desmosterol is decreased in the brain due to a decrease in the Dhxr24 gene (Wisniewski et al. 2013) . Consistent with this finding, Apoe KO mouse brains also exhibited decreased levels of desmosterol as early as 6 weeks of age while Ldlr KO mice showed a significant decrease at 12 weeks of age, suggesting that KO of either Apoe or Ldlr leads to perturbations in cholesterol and lipid metabolism that may promote Aβ formation and tau phosphorylation in the brain. The alterations observed in cholesterol metabolites as well as systemic cholesterol levels all direct these mouse models to being more susceptible to AD.
Epidemiological studies have shown that patients treated with DHA and eicosapentaenoate improved AD symptoms when they were in the early stages of the disease. Furthermore, administration of DHA and eicosapentaenoate in rodents showed reduced Aβ formation, ROS levels and oxidative Fig. 5 Loss of ApoE or Ldl-R causes subtle changes in histidine metabolism in the brain. a Biochemicals involved in histidine biochemistry from control, Ldlr KO and Apoe KO mouse brains were compared to determine if metabolomic analyses showed any statistically significant changes. There were only subtle changes in 1-methylimidazoleacetate and anserine. b A schematic of the histidine metabolism pathway. Data are expressed as mean ± SEM. Letters and lines indicate differences (p < 0.05) between control and Ldlr KO or control and Apoe KO mice (n = 6/group) stress in the cerebral cortex and the hippocampus, thus indicating that DHA plays a crucial role in alleviating the symptoms of AD (Hartmann et al. 2007; Lim et al. 2005; Oksman et al. 2006 ). In our metabolomic study, we observed subtle changes in these essential PUFAs that was time but not genotype dependent, which may suggest that age is a major factor in contributing to brain PUFA dysregulation in AD.
There was an increase in the histamine degradation product 1-methylimidazoleacetate. In addition, there was an increase in glutamine and acetyl glutamate derived from glutamate, indicating a perturbation in neurotransmission and brain function. In AD, histaminergic neurons also degenerate and form tangles in the brain. While histamine levels usually increase with age, a decline in histamine has been seen in AD, correlating with an impairment in cognitive function that leads to some of the symptoms seen in AD patients (Haas et al. 2008) . Histamine, which functions as a neurotransmitter in the CNS, is involved in many brain functions such as control of pituitary hormone secretion, suppression of eating, cognitive functions and sleep (Nuutinen and Panula 2010) . The release of histamine is altered in response to different types of brain injury and disease, and low histamine levels are known to be associated with convulsions and seizures (Bhowmik et al. 2012) . Therefore, increases in 1-methylimidazoleacetate as well as other histidine-derived metabolites may indicate a higher histamine turnover in Ldlr KO and Apoe KO mice, impairing cognitive function.
Metabolomic studies in human subjects have shown significant changes in amino acid metabolism in AD patients. Among these, the lysine metabolism pathway was one that showed significant alterations. Lysine also supports the synthesis of L-carnitine, which is needed to generate energy from fatty acids in mitochondria in cells other than neurons. AD patients were shown to have lower lysine catabolites and carnitine levels compared to control subjects (Trushina et al. 2013) . The lysine catabolites 2-aminoadipate and glutaroyl-carnitine were significantly reduced in the Apoe and Ldlr KO mice relative to controls, suggesting altered energy production in the KO animals relative to the wild type animals. Although overt changes were not observed in the dominant energy metabolism pathways such as glycolysis, TCA cycle, or β-oxidation, changes in several carnitine derivatives further support differences in homeostatic energy metabolism. Fig. 6 Loss of ApoE or Ldl-R results in altered lysine metabolism. Metabolomic analyses revealed that key metabolites in the lysine metabolism pathway were altered in Ldlr and Apoe KO mouse brains (n = 6/group). Letters and lines indicate differences (p < 0.05) between control and Ldlr KO or control and Apoe KO mice (n = 6/group) Therefore, this perturbation in lysine metabolism may potentiate neuropathology of aged Ldlr KO and Apoe KO mice.
Conclusion
Unbiased metabolomic profiling in young Apoe KO, Ldlr KO and WT mouse brains revealed subtle changes in a broad range of metabolites in vivo. These subtle changes in steadystate metabolites indicate that the loss of ApoE or Ldl-R alone does not significantly contribute to the progression of AD at an early stage in these mouse models.
